Introduction
Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting from mutations in gp91 phox , p22 phox , p47 phox or p67 phox subunits of the phagocyte nicotinamide dinucleotide phosphate oxidase. 1 Almost 75% of patients have the X-linked, gp91
phox -deficient form of CGD. CGD patients have recurrent life-threatening infections because phagocytes fail to produce microbicidal reactive oxygen species (ROS) such as superoxide and hydrogen peroxide. 2 Hematopoietic stem cell (HSC) transplantation can cure CGD, 3, 4 but most patients do not have a human lymphocyte antigenmatched healthy sibling, and transplantation carries the risk of graft failure, infection and graft versus host disease.
Somatic gene therapy targeting HSCs offer a promising treatment option for patients with CGD. g-Retroviral vectors in pre-clinical ex vivo and mouse knockout models of gene therapy for CGD have demonstrated significant correction of the oxidase defect. [5] [6] [7] Early clinical trials of ex vivo gene therapy for CGD used no chemotherapy conditioning of bone marrow (BM) and employed murine leukemia virus (MLV)-derived vectors to transduce CD34 + peripheral blood-mobilized stem cells (PBSCs). Following infusion of transduced PBSCs, fully oxidase-corrected neutrophils appeared in the peripheral blood at frequencies of 0.004-0.9%, but this number of cells was too low to provide clinical benefit. [8] [9] [10] In a recent clinical trial, the administration of busulfan chemotherapy conditioning BM prior to the infusion of autologous transduced PBSCs, together with the use of a gp91 phox -encoding spleen focus-forming virus-based vector resulted in unprecedented levels of gene marking in two X-CGD patients. 11 There appeared to be insertional activation of growth-promoting genes by enhancer elements in the vector long terminal repeat (LTR) region followed by vigorous oligoclonal cell expansion. Dependence on a single clone or small number of dominant clones for gene correction may enhance the risk of malignant transformation and increase the potential that genetic drift or loss of the dominant clone may occur, resulting in loss of therapeutic benefit. The risk of malignant transformation in patients receiving gene therapy is no longer just theoretical in that leukemias have been observed in four children with X-linked severe combined immunodeficiency, who received gene therapy with an MLV vector, where insertional mutagenesis may have played a significant role. 12, 13 Lentiviral vectors, such as vectors based on human immunodeficiency virus-1 (HIV-1), have become an attractive alternative for gene transfer into HSCs. In contrast to g-retroviral vectors, lentivectors do not require mitosis for integration 14 -an advantage for targeting long-term repopulating HSCs, which rarely undergo mitosis. 15 Lentiviral vectors easily accommodate a self-inactivating (SIN) design (deletion of enhancer/promoter sequences from the vector 3 0 LTR) enhancing their safety profile. Furthermore, it is suggested that they are less prone to gene silencing, 16 and there may be a safety benefit from an integration site preference that does not favor the 5 0 region of genes in contrast to g-retroviruses. 13, 17 However, safety studies regarding insertional mutagenesis due to lentiviral vector insertion sites in comparison to g-retroviral vectors are still limited and currently, intense studies focus on safety aspects of lentivectors for their potential use in clinical gene therapy trials.
Since HIV is a human pathogen, there are theoretical reasons to consider development of lentiviral vectors engineered from simian immunodeficiency viruses (SIV), which are less pathogenic for humans. 18 However, there are very few reported studies using SIV vectors to target human CD34 + HSCs with marker genes or using a therapeutic gene product. [19] [20] [21] Most lentiviral gene transfer studies have utilized vector particles pseudotyped with the vesicular stomatitis virus G-protein, which confers broad vector tropism and physical stability. 22 The major disadvantage of vesicular stomatitis virus G-protein is cytotoxicity from its fusogenic potential. A cytoplasmic tail-modified RD114 envelope (RD114/TR) is a non-cytotoxic alternative for pseudotyping lentivectors. 21, 23 The current study investigates the potential of an RD114/TR-pseudotyped SIVmac-derived vector encoding human gp91 phox for gene transfer into CD34 + PBSCs from human patients with X-CGD. Sustained gp91 phox expression and correction of oxidase function is achieved in the human X-CGD myeloid cells arising from the human xenograft in the marrow of nonobese diabetic/ severe combined immunodeficient (NOD/SCID) mice. This is the first demonstration that an RD114/TRpseudotyped SIV vector can reconstitute the oxidase defect in CGD.
Results
Efficient production of RD114/TR-pseudotyped SIV-lentiviral vector particles encoding gp91 phox The transfer vector is self-inactivating and derived from the non-pathogenic SIV macaque isolate 1A11. 24 Transcription of the therapeutic transgene gp91 phox is under control of the murine stem cell virus (MSCV) LTR enhancer/promoter acting as internal promoter (Figure 1a ). RD114/TR-pseudotyped vector particles were efficiently produced following transient transfection of 293T HEK cells resulting typically in titers of non-concentrated vector supernatant of 0.8-1.2 Â 10 5 infectious units (IU) ml À1 as determined on K562 cells. RD114/TR is a modified version of the feline endogenous virus envelope protein RD114 in that it is a chimeric protein, in which the cytoplasmatic tail has been replaced with that of the amphotropic MLV envelope. 21, 23 This envelope confers good physical stability and thus allows centrifugation to concentrate vector stocks. The averaged titer of 200-fold concentrated preparations was 1.5 Â 10 7 IU ml
À1
(n ¼ 7, Figure 1b ) and conferred potent oxidase activity when testing in a K562-X-CGD cell culture model (Figure 1c ).
Marking levels and correction of oxidase function in transduced X-CGD CD34 + PBSCs cultured ex vivo CD34 + PBSCs from two different X-CGD patients (P1 and P2) were placed in ex vivo culture and subjected to four transductions with RD114/TR-pseudotyped SIVmac vector encoding human gp91 phox at a multiplicity of infection (MOI) of 2-3. Similar cultures of non-transduced (naïve) PBSCs from both patients and from a healthy volunteer served as gp91 phox negative and normal positive controls, respectively. Ex vivo transduction efficiency (% of gp91 phox positive cells) determined at day 6 of culture was 40.5 and 46% in P1 and P2 cells, respectively (Figures 2a and b) . Only 5.6% of normal control CD34 + PBSCs was positive for expressed gp91 phox at this time point, since appearance depends on cell differentiation into phagocytic cells. Thus, PBSC samples were further cultured in media containing granulocytecolony-stimulating factor (G-CSF) to promote differentiation into granulocytes and expression of the gp91 phox was monitored over time in all cultures.
With HIV-1-derived lentivectors, it has been shown that non-integrated vector contributes to a significant degree to the high levels of marking early after infection. 25 In our own studies with the SIVmac vector, we noted that marking declined with prolonged culture (Figure 2c ), likely also reflecting loss of non-integrated vector transgene expression. Marking stabilized after about 14 days and was 22.7% (P1) and 27.1% (P2) at day 26 ( Figure 2c ). At this time point, 62.4% of normal control cells expressed gp91 phox . However, the mean fluorescence intensity (MFI) of fluorescent anti-gp91 phox signal in the gene-corrected patient PBSCs in culture was 38-39% of that seen with normal control cells in similar culture. This indicates that in transduced PBSCs, the expression of the gp91 phox transgene from the MSCV-LTR internal promoter in the SIN SIV lentivector does not reach expression levels of healthy phagocytes. Mean vector copy numbers in bulk transduced cells at day 26 of culture were 0.5470.08 (P1) and 0.6070.01 (P2), as determined by real-time quantitative PCR, implying an averaged copy number of 2.2-2.4 per stably transduced cell. To investigate if significant silencing occurred during the culture period, gp91 phox -negative sorted cells were analyzed. Mean vector copy numbers were 0.005770.0004 (P1) and 0.007670.0005 (P2), suggesting that there was hardly any silencing of the transgene in transduced cells within this time period.
Only normal cells and gene-corrected X-CGD cells that have matured into myeloid cells express and assemble all the complementary enzyme subunits required for oxidase function. Naïve and transduced CD34 + PBSCs from SIVmac gp91 phox correction of X-CGD N Naumann et al X-CGD patients and similarly cultured non-transduced CD34 + PBSCs from a healthy control were plated in semisolid collagen medium as described in the Materials and methods. At day 17 of culture, colonies were subjected to a nitroblue tetrazolium dye (NBT) test to detect respiratory burst activity. Plates with normal control PBSCs had 63/157 NBT-positive colonies, while P1 and P2 X-CGD plates had 0/162 and 0/143 NBTpositive colonies in the naïve group and 12/157 and 12/ 166 NBT-positive colonies in the transduced group, respectively. Thus, oxidase-positive colonies in the transduced X-CGD group were 18-19% of the healthy control. Liquid cell cultures at day 14 were analyzed by phorbol 12-myristate 13-acetate (PMA)-stimulated chemiluminescence assay. Superoxide generation levels by P1 and P2 naïve or transduced cultured PBSCs were o0.2 and o0.3 or 11.4 and 8.8% of the normal control cells, respectively. A dihydrorhodamine 123 (DHR) assay was performed to assess the level of oxidase activity by individual gene-corrected cells using samples at day 20 of culture. In cultures of PBSCs from healthy control 38.0% of cells had differentiated sufficiently to be oxidase positive in this flow cytometry assay. No cells from P1 or P2 were DHR positive in the naïve non-transduced cultures, but 5.8 and 3.45% of cells, respectively, from the transduced ones were DHR positive, corresponding to 15.3 and 9.1% of the normal cells (Figures 3a-c) . The average MFI in the gene-corrected P1 and P2 cell DHR assay was 33% of that seen with the normal control cells, indicating that on a per cell basis, oxidase activity was /TR-pseudotyped SIV vector particles were transiently produced from 293T HEK cells using a 4-plasmid cotransfection and concentrated (200-fold) by high-speed (18 600 g) centrifugation. Key: eCMV, cytomegalovirus enhancer, which is in place of the U3 region of the 5 0 LTR, 5 0 long terminal repeat; Dgag and Dpol, gag-pol coding sequence with a created frame shift and termination codon; RRE, rev-responsive element; SA, splice acceptor site; MSCV-LTR, murine stem cell virus enhancer/promoter acting as internal promoter; SIN-LTR, 3
0 LTR with a deletion in the U3 region generating a selfinactivating vector and with rBGpA, rabbit b-globin polyadenylation sequence, which is in place of the U5 region; SV40ori, simian virus 40 origin of replication. (b) The percent of K562 cells expressing gp91 phox transgene after a single overnight transduction with different dilutions of concentrated vector preparations (n ¼ 7) using 1 Â 10 5 K562 cells as target in 1 ml total volume. Using the linear portion of the curve (p10 ml concentrate per ml culture medium), the mean titer of the vector concentrates was determined to be 1.5 Â 10 7 70.6 Â 10 7 IU/ml (n ¼ 7). Maximum transduction (E80%) was achieved at a concentrate dilution of 1:20 at a calculated MOI of 7.5. (c) These chemiluminescence assays (x axis-incubation time in minutes; y axis -relative light units) measure PMA-stimulated ROS production from 1 Â 10 5 K562-X-CGD cells (already contain p47 phox and p67 phox transgene and native p22 phox ) before (naïve; left) and after (transduced; middle) a single overnight transduction with vector at a MOI of 2.25 (resulting in a E50% transduction efficiency). As a comparison, the stimulated ROS production from an equivalent number (0.5 Â 10 6 ), normal human granulocytes is shown at the right indicating that ROS production by transduced K562-X-CGD cells is similar to that of normal human granulocytes. Shown below the representative graph is the calculated activity in light units per 40 min per 0.5 Â 10 6 gp91 phox -positive cells for each group (n ¼ 3). LTR, long terminal repeat; MOI, multiplicity of infection; MSCV, murine stem cell virus; PMA, phorbol 12-myristate 13-acetate; ROS, reactive oxygen species; SIN, self-inactivating; SIV, simian immunodeficiency virus; X-CGD, X-linked chronic granulomatous disease.
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phox correction of X-CGD N Naumann et al about one-third of healthy control. Interestingly, as will be noted below, the level of oxidase correction was significantly higher (almost 60% of control), when we assessed gene-corrected myeloid cells matured in vivo in the NOD/SCID mouse xenograft model.
Engraftment of human CD34
+ PBSCs and gp91 phox expression in human myeloid cells in the NOD/SCID mouse human-xenograft transplant model
To determine transduction efficiencies in BM-repopulating HSCs, NOD/SCID mice were transplanted with transduced X-CGD PBSCs from P1 and P2. Mice injected with naïve patient PBSCs and normal PBSCs from the healthy volunteer served as gp91 phox negative and positive controls, respectively. Human cell chimerism as determined by the percentage of CD45 + cells (human leukocytes) present in mouse BM ranged from 36.8 to 75.7% at 6 weeks post-transplant (Table 1) [26] [27] [28] Dihydrorhodamine 123 assay at day 21 of the liquid culture demonstrated that 2.7% (P1) and 2.0% (P2) of the cells were DHR-positive when compared to normal CD34 + cells that have differentiated in culture for the same time period. The left over cell population from the CD34 + selection procedure containing already maturing and fully differentiated human myeloid cells (negative fraction, CD34 + -depleted) was also kept in culture medium-containing cytokines specific for human hematopoietic cells to outgrow any contaminating murine 
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phox correction of X-CGD N Naumann et al cells. DHR assay performed on these samples at day 21 revealed a robust oxidase response in approximately 3.5-4.4% of the cells compared to normal control, whereas the naïve patient cell controls did not show any response (Figures 5d-f ). The average oxidase activity level per corrected phagocytic cell was estimated E59% of normal control by comparing the MFIs of DHR-positive transduced X-CGD cells to DHR-positive control cells.
Integration site analysis of transduced X-CGD CD34 + cells
Linear amplification mediated (LAM)-PCR was performed on DNA samples (6 Â 100 ng per sample) from 26 days ex vivo cultured transduced X-CGD PBSCs and CD34 + cells isolated from chimeric mouse BM. Gel analysis of PCR products revealed a polyclonal pattern for all samples ( Figure 6 ). To further validate vector integrations, LAM-PCR products were cloned and sequenced. A total of 97 distinct insertion sites could be mapped to the human genome. Thirty-nine and 37 insertion sites are derived from ex vivo cultured transduced PBSCs from P1 and P2, respectively, and 11 (P1) and 10 sites (P2) from CD34 + cells isolated from xenograft BM as summarized in Table 2 and  Supplementary Table 1 . The majority (77.3%; 75/97) of integration sites were located within transcription units, whereby 73 inserts (75.2%) were found within introns of RefSeq genes and only two (2.1%) within exons. We did not detect an orientation preference for insertion of the SIVmac vector. Only 20 out of 97 inserts (20.6%) landed within a 10 kb window upstream and downstream of transcription start sites of genes, only seven (7.2%) within a 75 kb window. Chromosome 19, which is the most gene-dense chromosome, was targeted most frequently with 0.24 inserts per Mbp followed by other relatively gene-dense chromosomes 17, 16 and 22 with 0.22, 0.09 and 0.06 inserts per Mbp, respectively. We did not observe any integrations on chromosomes 5, 13, 18, X and Y with our data set. In 20 cases of the found insertions, the next RefSeq gene is listed in the Retrovirus Tagged Cancer Gene Database (RTCGD), with 11 of these being common integration sites (Supplementary Table 1) . Interestingly, out of 97 distinct inserts, we found two hits within the same RefSeq gene NFATC3 on chromosome 16q22.1. Both integrations occurred in the same intron, approximately 15.6 kb apart. NFATC3 has been also found as gene that has been targeted more than once by the SIVmac vector in rhesus macaque HSCs in a detailed integration site study by Hematti et al. 29 Furthermore, we also detected one insertion within Thus, the P1 cell group was 4.4% positive compared to normal control. Of particular interest is that in the matured transduced X-CGD cells derived from the xenografted mice, the MFI as an indicator of ROS production per DHR-positive cell was E59% of the normal control value. BM, bone marrow; DHR, dihydrorhodamine 123; MFI, mean fluorescence intensity; NBT, nitroblue tetrazolium dye; NOD/SCID, nonobese diabetic/severe combined immunodeficient; PBSC, peripheral blood-mobilized stem cell; ROS, reactive oxygen species; X-CGD, X-linked chronic granulomatous disease.
phox correction of X-CGD N Naumann et al PACS1, which has been identified as common integration site in this previously published study as well.
Discussion
In the current study, we transduced human X-CGD CD34 + PBSCs using a SIN RD114/TR-pseudotyped SIVmac-derived lentiviral vector encoding gp91 phox . Transduction conferred sustained expression of the gp91 phox transgene and oxidase activity in human myeloid cells differentiating ex vivo as well as in vivo in the NOD/SCID mouse xenograft model. A strong incentive for development of several SIV vector systems in a number of laboratories 30 was the desire to be able to study the performance of lentivectors in non-human primates because restriction factors prevent HIV-1-based lentivectors from transducing simian cells efficiently.
18,31 SIV vector systems might also be an attractive tool for human gene therapy. However, there is surprisingly limited information regarding the performance of SIV vectors for gene transfer into human HSCs. So far, there have only been a few studies reported, in which human CD34 + cells have been targeted by SIV vectors carrying a marker gene, 19, 21 and to our knowledge only one study investigating transfer of a therapeutic gene (clotting factor VIII) into repopulating human CD34 + HSCs. 20 The latter study utilized a vector based on SIVagmTYO and demonstrated sustained transgene expression in transduced human cord blood CD34 + cells that were transplanted into NOD/SCID mice.
The SIVmac 1A11 vector that we employed in our studies was chosen because of the non-pathogenic character of the parent virus, its low nucleotide homology with HIV-1 and because of its reported performance in achieving long-term transgene expression in a green fluorescent protein-marking study in rhesus macaques, although a lower efficiency in targeting human CD34 + and colony forming progenitor cells ex vivo relative to an HIV-1-based vector has been noted in the same study. 24 This SIV vector system incorporates the most current lentiviral vector safety features, including the SIN design of the transfer vector and the absence of accessory protein genes, as well as that the rev/tat element is present on a separate plasmid, making it suitable for potential clinical application. Additional advantages might include the lack of seroconversion to HIV positivity after vector exposure 29 and no inhibition by the human TRIM5a protein, which can at least moderately restrict infection of human cells by HIV-1 vectors. 31 It is of note that we chose a modified version of the feline endogenous virus envelope protein (RD114/TR) to package our SIVmac vector instead of the more widely used vesicular stomatitis virus G-protein envelope. Numerous studies with g-retro-and lentivirus vectors pseudotyped with RD114 or its modified versions highlight the excellent performance for targeting human + cells isolated at 6 weeks from chimeric xenograft mouse BM from mice that received transplants with transduced P1 and P2 X-CGD PBSCs (lanes 2 and 4, respectively) were subjected to LAM-PCR. PCR products of six parallel reactions were pooled per sample and resolved on a high resolution Spreadex gel. Multiple bands were present in all samples, suggesting polyclonal marking. The bp, H 2 O, and n indicate the 100 bp sizing ladder, water control, and naïve PBSC control, respectively. BM, bone marrow; LAM-PCR, linear amplification mediated-PCR; PBSC, peripheral blood-mobilized stem cell; SIV, simian immunodeficiency virus; X-CGD, X-linked chronic granulomatous disease. 
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À cells express high levels of the neutral amino-acid transporter that functions as receptor for RD114. 34 As we can use large-scale concentration of vector supernatants (up to 3 l per run) by highspeed (non-ultra) centrifugation as performed in the current study, it is possible to concentrate a variety of vector preparations of different starting titers to hightiter vector stocks of 41 Â 10 7 IU ml
À1
, as determined on the human erythroleukemia cell line K562.
In the study presented here, G-CSF-mobilized CD34 + PBSCs served as target cells. This source of HSCs is easy to obtain and represents the target of choice for most clinical applications of hematopoietic gene therapy. An important rational for the use of lentiviral vectors for HSC gene therapy is their ability to transduce nonmitotic cells, making such vectors a good choice for targeting primitive HSCs, which are known to be mostly quiescent and relatively slow to go into cell division in culture. 35 Nonetheless, it is also well reported that lentiviral tranduction efficiency is greatly enhanced if CD34 + HSCs are cultured in cytokine-supplemented media to promote cell proliferation or at least progression from G 0 to G 1 phase of the cell cycle. 26, 36 Thus, for our studies, we cultured and transduced PBSCs under proliferation-permissive conditions. We achieved initial ex vivo gp91 phox transgene marking levels of 40.5-46% in PBSCs from two different patients with X-CGD by transduction with a SIVmac lentiviral vector. These levels declined and stabilized at 22.7 and 27.1% at day 26 of ex vivo culture. Although this final stable ex vivo transduction rate is modest, it none the less resulted in significant proportions of gp91 phox -positive myeloid cells arising in vivo in the NOD/SCID chimeras of up to E10% compared to healthy control, suggesting that progenitor cells with repopulating potential were well targeted. Furthermore, we found sustained transgene expression and oxidase function in patient CD34 + cells isolated from chimeric mouse BM and differentiating in culture and demonstrated the presence of multiple vector integration sites in these cells.
We note that in vivo expression of gp91 phox per genecorrected myeloid cell was approximately 20% of the expression level per normal cell. This is consistent with previous observations that expression of third generation HIV-1 SIN lentivector-transferred gp91 phox seems to be less efficient than native expression of gp91 phox in normal human myeloid cells and even of expression of gp91 phox transgene mediated by MFGS-gp91 pohx , an MLV-based oncoretroviral vector. 26, 34, 37 However, studies suggest that even moderate levels of gp91 phox expression per cell of only about 20-25% of healthy control can result in significantly higher relative levels up to full restoration of the oxidase enzyme activity per phagocyte. 7, 38 This is consistent with our current data for matured human myeloid cells derived from chimeric mouse BM, where we find a relatively higher level of oxidase function of almost 60% of normal control per gene-corrected cell, while gp91
phox expression was about 20%. In fact, in a recently reported gene therapy trial for X-CGD, in which two patients clearly derived significant clinical benefit in the cure of ongoing infections from the ex vivo gene therapy, the reported oxidase activity per transduced circulating neutrophil was 15-30% of that of normal neutrophils at a time when only 20% of circulating cells were gene-corrected. 11 We show here that the SIVmac vector we used performed at least as well on a per corrected cell basis as the g-retroviral vector that clearly achieved clinical benefit.
As already noted with respect to the recent X-CGD gene therapy trial, full reconstitution of oxidase activity is not required for a clinically improved phenotype, as can also be concluded from the observation that only 5-10% of normal ROS-producing neutrophils in human female X-CGD carriers seem to prevent severe infections. 39 Furthermore, various studies with CGD mouse models also support this assumption. 6, 40 In addition, HSC gene therapy for CGD resulting in even a low level and short-term production of ROS by phagocytes might provide clinical benefit especially for high-risk patients suffering from severe infections resistant to conventional treatment.
Even so, more elevated levels of gp91 phox expression and oxidase activity on a per cell basis are highly desirable. This aim might be achievable by changing the internal promoter driving transgene expression, although the MSCV-LTR promoter used in the current study is considered to be a particularly strong promoter. 41 Another approach is to incorporate insulator elements into the vector backbone flanking the transgene to prevent negative influences on transcription by genomic sequences adjacent to the vector integration sites. 42 One straightforward approach would seem to be just to use higher MOIs. However, there is a theoretical increase in safety risk to higher vector insert copies per cell. 27 Thus, it would be safer to aim to achieve higher efficiency of transgene expression per vector copy.
Overall, lentiviral vectors are promising for gene therapy of myeloid immunodeficiencies in terms of their efficiency in transducing long-term primitive HSCs and hypothetical safety advantages compared to g-retroviral vectors due to their insertion site preferences. 17 In consistency with previously published SIV vector integration site studies in rhesus 29 and human 43 cells, we found a strong preference of the SIVmac vector to integrate within transcription units. Genedense chromosomes (16, 17, 19 and 22) were especially targeted. Only 7.2% of inserts were detected within a 75 kb window around transcription start sites (TSS), which is similar to what has been described for HIV-1-based vectors but significantly less compared to g-retroviral vectors based on MLV. 17, 29, 43 Thus, this decrease in relative targeting of transcription start sites by lentivectors may result in a lower risk to cause insertional mutagenesis by influencing promoter driven transcription of onco/protooncogenes. In fact, recent data provide evidence for low genotoxicity potential of lentiviral vector integrations. 44 It needs to be seen if SIV-derived vectors represent a convincing alternative to HIV-1-based lentivectors. Secondary/tertiary NOD/SCID mouse transplant studies as well as further large animal studies will be important to better demonstrate the efficiency in targeting very primitive long-term HSCs and to define the safety profile of SIVmac-based vectors for possible clinical applications. So far, no adverse events have been observed in three rhesus monkeys transplanted with autologous HSCs transduced with the same SIVmac vector backbone used in the study reported here, but encoding only green fluorescent protein.
24,45
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In summary, our study for the first time demonstrates performance of a gp91 phox -encoding RD114/TR-pseudotyped SIVmac-based vector in targeting NOD/SCIDrepopulating X-CGD CD34 + PBSCs. We observed sustained gp91 phox expression and significant correction of the oxidase defect in transduced human X-CGD myeloid cells. Thus, SIVmac-derived lentivectors might represent a feasible tool and are worth exploring for their use in gene therapy for CGD and other hereditary hematopoietic/immunologic diseases.
Materials and methods

SIV-derived vector construction and production
The open-reading frame of the human gp91 phox cDNA was used to replace the green fluorescent protein cDNA sequence in the parental SIVmac 1A11 vector plasmid pCL20cSLFR MSCV-green fluorescent protein, 24 constructed by Hanawa et al., using the Age I and Bst1107 I restriction enzyme sites. Sequencing confirmed vector accuracy. RD114/TR-pseudotyped SIV lentiviral particles were generated by transient 4-plasmid cotransfection of 293T HEK cells. 293T HEK cells (4.5 Â 10 6 ) were seeded onto 10 cm dishes the day before transfection and cultured in 10 ml IMDM supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine (200 mM) and 50 U ml À1 penicillin per 50 mg ml À1 streptomycin. After replacement of culture medium cells were transfected using the calcium-phosphate precipitation method with a plasmid DNA mixture of 20 mg transfer vector, 12 mg pCAG-SIVgprre, 5 mg pCAG4-RTR-SIV and 10 mg phCMV-RD+ (RD114/TR). After 16-18 h, cells were washed with phosphate-buffered saline and re-fed with fresh medium. Harvest of supernatants containing lentiviral vector started after another 24 h for 3 consecutive days. Virus supernatant was filtered, concentrated 200-fold by high-speed centrifugation (18 600 g, 4 h, 4 1C; Avanti J-E centrifuge, rotor JLA 10.500; Beckman Coulter, Fullerton, CA, USA), and frozen immediately at À80 1C until further used.
Collection of CD34 + PBSCs
One healthy volunteer and two patients (P1 and P2) with X-linked CGD received five daily subcutaneous injections of 10 mg kg À1 G-CSF) after obtaining informed consent (NIH Institutional Review Board-approved protocols 94-I-0073 and 95-I-0134). On days 5 and 6, PBSCs were collected by apheresis and CD34 + PBSCs selection was performed using immunomagnetic beads (ISOLEX300i system; Baxter Healthcare, Deerfield, IL, USA). The human CD34 + cells, immune-selected to 80-90% purity were cryopreserved in liquid nitrogen until further use.
Culture and transduction procedures for K562 cell lines and CD34 + PBSC
The human erythroleukemia cell line K562 that naturally does not express the nicotinamide dinucleotide phosphate oxidase components p47 phox , p67 phox and gp91 phox was cultured in RPMI1640 supplemented with 10% FBS, and 50 U ml À1 penicillin+50 mg ml À1 streptomycin. This cell line was used for vector titering. We also used a K562 model of X-linked CGD (K562-X-CGD) 46 ), and interleukin-3 (10 ng ml À1 ). For each mouse that would be transplanted at the end of the transduction or control culture, we added at the initiation of culture 3 Â 10 6 human CD34 + PBSC from a CGD patient or healthy volunteer. Naïve (non-transduced) X-CGD PBSCs from P1 and P2 and PBSCs from a healthy volunteer served as negative and positive controls for gp91 phox expression and oxidase function, respectively. Expansion over the 5 days of culture/transduction was 9.2-to 11.3-fold and all of the progeny of that expansion from the 3 Â 10 6 cells per mouse at initiation of culture were transplanted into each recipient NOD/SCID mouse. After 24 h prestimulation, CD34
+ cells were transferred into Retronectin-coated six-well plates and transduced four times overnight using concentrated vector with a MOI of about 2-3. The other transduction conditions were as described before. At culture day 5, cells were washed twice with phosphate-buffered saline and most of the cells resuspended in phosphate-buffered saline+1% bovine serum albumin for intravenous injection into NOD/SCID mice as described in the next section. However, a small sample of the cells from each group was maintained in ex vivo culture in the same medium as above, but with addition of 10 ng ml À1 G-CSF.
Transplantation of CD34 + PBSCs into NOD/SCID mice
Cultured CD34 + PBSCs (27 to 32 Â 10 6 per mouse represented the progeny of expansion in culture from 3 Â 10 6 at initiation of culture) were transplanted by tailvein injection into 8-to 9-week-old NOD/SCID mice (Jackson Laboratory, Bar Harbor, ME, USA) that were sublethally irradiated (300 cGy) 2 days before transplantation. Mice also received an intraperitoneal injection of 1 mg TM-b1 antibody (anti-CD122) 47 on the day of transplantation to improve human cell engraftment. BM was harvested 6 weeks post-transplant for analysis of engraftment and transgene expression levels.
Analysis of gp91
phox expression and human cell engraftment Expression of gp91 phox in ex vivo cultured cells as well as in cells derived from chimeric mouse BM was determined by flow cytometry. Cells were stained with murine monoclonal antibody 7D5 48 followed by a secondary fluorescein isothiocyanate-conjugated rat anti-mouse antibody (Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA). Human cell engraftment in xenotransplanted mice was analyzed using a phycoerythrin-conjugated anti-human CD45 antibody for detection of all human leukocytes and an allophycocyaninconjugated anti-human CD13 antibody for human SIVmac gp91 phox correction of X-CGD N Naumann et al myeloid cells (BD Biosciences, San Jose, CA, USA). Engrafted human CD34 + cells from transplanted mice (pooled within one experimental group) were positively selected using the MACS direct CD34 progenitor cell isolation kit (Miltenyi Biotec Inc., Auburn, CA, USA). These cells were then either used for colony assays or cultured in liquid medium supplemented with the cytokines specific for human CD34 + as described before including 10 ng ml À1 G-CSF.
Assessment of corrected oxidase activity
Functionality of vector-transferred gp91 phox (ROS production) was first proven in transduced K562-X-CGD cells using a chemiluminescence assay as described previously.
26,49 CD34 + cells were plated for colony assays in semisolid collagen medium supplemented with the cytokines used for liquid culture except for thrombopoietin and interleukin-6 but with addition of 40 ng ml À1 G-CSF and 10 ng ml À1 granulocyte-macrophage CSF according to the manufacturer's protocol (CollagenCult; StemCell Technologies Inc., Vancouver, BC, Canada) at day 5 of culture or after selection from chimeric mouse BM (duplicates of 2200 cells per 1.2 ml medium per well). Generation of superoxide in myeloid colonies was then evaluated by PMA-stimulated NBT test at days 16-17 of culture as described previously. 49 Colonies with intense staining were scored positive. PMA-stimulated ROS production by myeloid cells arising in liquid culture was also assessed by chemiluminescence assay at day 14 and using the flow cytometry DHR assay at days 20-21.
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Evaluation of vector copy number and integration sites Genomic DNA was extracted from ex vivo cultured cells and from human CD34 + cells isolated from chimeric mouse BM. Vector copy number was estimated by quantitative real-time PCR. Sequences of both the SIV vector and the human house keeping gene phenol sulfotransferase were amplified in the same well to allow normalization of DNA input most accurately (multiplex approach). The following primer/probe set was used for the SIV vector: forward primer: 5 0 -ACCAGGCACTGCCAACCAGAGAA-3 0 ; reverse primer: 5 0 -ATCGAAGCTGGGCCCGTTAACG-3 0 ; probe: 5 0 -FAM-GAACCACCGCCTTCTCCACCGTCT-TAMRA-3 0 . The primers and probe for phenol sulfotransferase were: forward primer: 5 0 -GGTGCCCTTCCTTGAGTTCA-3 0 ; reverse primer: 5 0 -CCCCTTGCACCCAGGAC-3 0 ; probe: 5 0 -VIC-CCCCAGGGATTCCCTCAGGTGTGT-TAMRA-3 0 . All samples of interest were analyzed in duplicates using the 7500 Real Time PCR System (Applied Biosystems, Foster City, CA, USA) under following PCR conditions: 2 min at 50 1C, 10 min at 95 1C, 40 cycles of 15 s at 95 1C and 60 s at 60 1C. Standard curves were established for both SIV and phenol sulfotransferase by analyzing samples of serial dilutions of DNA from a K562 cell line with a single copy of SIV vector per cell. A previously reported LAM-PCR protocol modified for the SIV vector 24 was performed with six different reactions per DNA sample and pooling after the last PCR step. Six microliter from each pooled product were separated on a high-resolution gel (Spreadex EL 800; Elchrom Scientific AG, Cham, Switzerland). Purified LAM-PCR products from the CD34 + cell samples derived from chimeric xenograft mouse BM were shotgun cloned (TOPO TA Cloning Kit; Invitrogen, Carlsbad, CA, USA) and sequenced on a CEQ 8000 Genetic Analysis System (Beckman Coulter, Fullerton, CA, USA). A sequence was accepted as valid integration site if a part of the SIV vector LTR region was present and the adjacent sequence could be assigned to a human genomic sequence. The University of California, Santa Cruz (UCSC) genome browser (BLAT search, assembly: March 2006) was utilized for alignment with the human genome. For further analysis, we also used the Ensembl Genome Browser (release 43, February 2007) and the Retrovirus Tagged Cancer Gene Database (RTCGD mm8).
